Complement factors B, D, C3bBbP and risk of future venous thromboembolism

Espen W Skjeflo; Line H Evensen; Søren B Jensen; Nadezhda Latysheva; Annika Michelsen; Thor Ueland; Sigrid K Brækkan; Kristian Hindberg; Omri Snir; Tom Eirik Mollnes; John-Bjarne Hansen

doi:10.1016/j.clim.2023.109278

Complement factors B, D, C3bBbP and risk of future venous thromboembolism

Clin Immunol. 2023 Apr:249:109278. doi: 10.1016/j.clim.2023.109278. Epub 2023 Mar 7.

Affiliations

¹ K.G. Jebsen - Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, University of Tromsø - The Arctic University of Norway, Tromsø, Norway; Research Laboratory, Nordland Hospital, Bodø, Norway. Electronic address: espenwskjeflo@gmail.com.
² K.G. Jebsen - Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, University of Tromsø - The Arctic University of Norway, Tromsø, Norway.
³ Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.
⁴ K.G. Jebsen - Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, University of Tromsø - The Arctic University of Norway, Tromsø, Norway; Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.
⁵ K.G. Jebsen - Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, University of Tromsø - The Arctic University of Norway, Tromsø, Norway; Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway.
⁶ K.G. Jebsen - Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, University of Tromsø - The Arctic University of Norway, Tromsø, Norway; Research Laboratory, Nordland Hospital, Bodø, Norway; Department of Immunology, Oslo University Hospital and University of Oslo, Norway; Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, Trondheim, Norway.

PMID: 36894046
DOI: 10.1016/j.clim.2023.109278

Abstract

The complement system appears to be involved in the pathogenesis of venous thromboembolism (VTE). We investigated the association of complement factors (CF) B, D, and the alternative pathway convertase, C3bBbP, measured at inclusion, with the risk of future VTE in a nested case-control study; 380 VTE patients and 804 age- and sex-matched controls derived from the Tromsø study. Odds ratios (ORs) with 95% confidence intervals (95% CI) for VTE across tertiles of CF concentrations were estimated using logistic regression. There was no association between CFB or CFD and risk of future VTE. Higher levels of C3bBbP gave an increased risk of provoked VTE; subjects in Q4 had a 1.68-fold higher OR compared with Q1 in the age-, sex- and BMI-adjusted model (OR 1.68; 95% CI 1.08-2.64). There was no increased risk of future VTE in individuals with higher levels of complement factors B or D of the alternative pathway. Increased levels of the alternative pathway activation product, C3bBbP, showed an association with future risk of provoked VTE.

Keywords: Blood coagulation; Case-control studies; Complement system proteins; Logistic models; Venous thromboembolism.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Case-Control Studies
Complement Factor B
Humans
Risk Factors
Venous Thromboembolism* / etiology

Substances

Complement Factor B